Charles River Laboratories Intl. Inc vs Roblox Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $225.52 (market cap $11.14B), while Roblox Corp trades at $56.62 (market cap $39.00B). The key difference: Roblox Corp is far larger — about 3.5× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| CRL | RBLX | |
|---|---|---|
Market Cap | $11.14B | $39.00B |
Sector | Health | Media |
52-Week High | $233.60 | $141.56 |
52-Week Low | $145.57 | $41.30 |
Enterprise Value | $14.00B | $37.59B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Roblox (RBLX) trades at $55.085, down 0.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.62. Revenue grew to $4.89 billion in 2025, though net losses persist at -$1.07 billion. The stock faces headwinds from multiple class-action lawsuits filed in July 2026 alleging securities fraud, but operational cash flow improved to $1.8 billion, supporting ongoing platform investments.
The outlook balances robust user growth and cash generation against profitability challenges and legal risks. Upside exists if monetization improves and legal issues resolve, but high P/B of 91.2 and negative margins warrant caution. Analysts remain predominantly bullish (51% buy ratings), viewing recent declines as a buying opportunity for long-term platform expansion.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →